Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Add-on buprenorphine at analgesic doses for the treatment of severe suicidal ideas during a major depressive episode
2018-003816-38Phase 2Active
- Sponsor
- CHU Nîmes
- Start
- Jun 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of buprenorphine in major depressive disorder (MDD) and suicidal ideation (3 arms), sponsored by CHU Nîmes. Primary endpoint: Scores on the Scale for Suicidal Ideation at Day 7. Started Jun 2020; status: active.
02
Drugs
buprenorphine
03
Conditions
major depressive disorder (MDD)suicidal ideation
Beyond the preview
Go deeper on 2018-003816-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003816-38.